Approximately 51,000 subjects in each arm would be required to compare OBS with not undertaking such surgery, with subsequent development of ovarian cancer as primary outcome. A randomised trial with menopause as the primary outcome will require 3513 subjects/arm, with 5 year follow up, for a HR=1.2 for menopause (at 90% power and α=0.05). This will addresses key issues of menopause/ long-term health outcomes and is feasible. The argument for change in practice needs to be driven by the magnitude of 'additional' benefit of OBS on ovarian cancer-risk, weighed against logistics of delivery, implications on training needs, potential complications, cost-effectiveness, impact on menopause and long-term health outcomes. Well-designed trials are needed to achieve this.
Disclosure of Interests
RM declares no conflict of interest. UM has a financial interest in Abcodia, Ltd., which has an interest in ovarian cancer screening and biomarkers for screening and risk prediction.
Funding
The commentary is not funded by any charity or grant.
